Early detection, increase cure rate and reduce mortality. The cure rate of early cancer is much higher than that of the middle and late stages, and the side effects of treatment are limited. The cure rate of early-detected cancer is over 90%, so it’s particularly important to do early cancer detection.
Alercell is dedicated to find early detection process through DNA sequencing to assist all patients as early as possible, even preventing the ultimate scope.
TO COME IN 2024
ROS1 Fusions Detection Kit.
The recognition of gene fusion promises an important step in personalized decisions for cancer treatment. One such biomarker that is looked for in non-small-cell lung cancer (NSCLC) is inaccuracy in the ROS1 gene. In NSCLC patients, the fusion of the ROS1 gene takes place with a portion of another gene. This results in the activation of the ROS1 gene and the outcome is an uncontrolled growth of cells and ultimately cancer.
For Breast Cancer
BRCA1 stands for Breast Cancer Gene 1. New DNA sequencing test are targeting early and precise detection of Breast & Ovarian cancer diagnosis. BRCA 1 & BRCA2 are tumor suppressor genes, which are involved in DNA damage repair